Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience

MLA

Prosanta Mondal, et al. “Outcomes of First-Line FOLFIRINOX (FFX) versus Gemcitabine and Nab-Paclitaxel (GN) in Patients with Advanced Pancreatic Cancer: Multi-Institutional Canadian Sites Experience.” Annals of Oncology, vol. 30, Oct. 2019, p. v267. EBSCOhost, https://doi.org/10.1093/annonc/mdz247.028.

APA

Prosanta Mondal, Gerald Batist, A. Papneja, Ivan Barrera, Sarah Mustafa Ahmed, Petr Kavan, & N. Papneja. (2019). Outcomes of first-line FOLFIRINOX (FFX) versus gemcitabine and nab-paclitaxel (GN) in patients with advanced pancreatic cancer: Multi-Institutional Canadian sites experience. Annals of Oncology, 30, v267. https://doi.org/10.1093/annonc/mdz247.028

Chicago

Prosanta Mondal, Gerald Batist, A. Papneja, Ivan Barrera, Sarah Mustafa Ahmed, Petr Kavan, and N. Papneja. 2019. “Outcomes of First-Line FOLFIRINOX (FFX) versus Gemcitabine and Nab-Paclitaxel (GN) in Patients with Advanced Pancreatic Cancer: Multi-Institutional Canadian Sites Experience.” Annals of Oncology 30 (October): v267. doi:10.1093/annonc/mdz247.028.